Evidence mapPaperPMID 42441014Full record

ArticleTH open : companion journal to thrombosis and haemostasis2026

Normalization of Haemostasis in People with Haemophilia A: Expert Consensus on Unmet Needs and a Framework for Advancing Towards Health Equity.

Cedric Hermans, Günter Auerswald, Ruben Berrueco, Gonzalo Calvo, Panagiotis Christoforou, Daniel Anibal-García Diego, Enrico Ferri Grazzi, Paul McLaughlin, Flora Peyvandi, Jan Pucek and 3 more

Abstract read
In one paragraph

Article in TH open : companion journal to thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cedric HermansDivision of Haematology, Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Günter AuerswaldCoagulation Centre, Bremen Central Clinic, GeNo Ltd., Parent-Child-Centre Prof. Hess, Bremen, Germany.
Ruben BerruecoServicio de Hematología Pediátrica, Hospital Sant Joan de Déu de Barcelona, Universitat de Barcelona, Barcelona, Spain.
Gonzalo CalvoEuropean Association for Clinical Pharmacology and Therapeutics, Barcelona, Spain.
Panagiotis ChristoforouBlood Unit and National Reference Center for Congenital Bleeding Disorders, "Laiko" General Hospital, Athens, Greece.
Daniel Anibal-García DiegoFedhemo (Federación Española de Hemofilia), Madrid, Spain.
Enrico Ferri GrazziFedEmo (Federazione delle associazioni Emofilici), Milan, Italy.
Paul McLaughlinKatharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
Flora PeyvandiFondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Jan PucekCzech Society of Hemophilia, Prague, Czech Republic.
Martin SedminaSlovak Hemophilia Society, Bratislava, Slovakia.
Susan ShapiroOxford Haemophilia and Thrombosis Centre, Oxford University Hospitals, Oxford, United Kingdom.
Mark W SkinnerInstitute for Policy Advancement Ltd, Washington, District of Columbia, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New therapies for haemophilia A have created momentum for enhancing protection against bleeding. Objective: The ultimate objective is to address remaining unmet needs and promote health equity. Methods: In this initiative, 14 haemophilia A experts from Europe ( Results: Among the panellists who voted, consensus was reached on 25/26 statements, including 13 with 100% agreement. The experts outlined a need to optimize prophylaxis in all eligible PwHA, aiming for high-sustained FVIII levels or normalized haemostasis. The panel also highlighted a need to prevent all bleeds (including microbleeds) that can occur despite prophylaxis, and to address chronic pain which is highly prevalent. Overall, 23 policy recommendations were finalized, which included the wider use of prophylaxis to reduce the burden of disease on PwHA and/or provide normalized haemostasis, the expansion of multidisciplinary teams and the establishment of networks of expertise, and sharing of specialist knowledge. Conclusion: This initiative lays an ambitious foundation to rigorously evaluate unmet needs in PwHA and the determinants of health equity, offering a comprehensive set of recommendations to overcome barriers and achieve the possibility of normalization of haemostasis.

Indexed as

consensushaemophilia Ahealth equitytreatment outcome

Identifiers

PMID42441014
PMCPMC13334954

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.